Life Sciences

Life sciences organizations face the challenge of converting great discoveries and research breakthroughs into public acceptance and market success. For companies specializing in pharmaceuticals, biotechnology, medical products and technology and medical devices, the life sciences are changing at a remarkable rate.  Deloitte LLP’s Life Sciences practice works with our clients to shape the evolution of the industry. Learn more about our Health Sciences practice and Deloitte Recap. 

More Featured Insights

  • New Commercial Model: Science or Swag?
    New Commercial Model: Science or Swag?
    Should pharmaceutical companies change how they sell, or stick with the status quo? Explore this Deloitte Debate from a life sciences perspective.
  • Secure Supply Chain 2015 for Life Sciences
    In order to succeed and strive beyond 2015 Life Sciences organizations need to make the Supply Chain a strategic priority. Learn what to focus on.
  • What Payers Want
    Life Sciences manufacturers will need to reevaluate their current relationships with health care payers and build new capabilities that focus more on the needs of their true customers. Learn more.
  • M&A and Life Sciences
    M&A and Life Sciences
    By 2012 drugs representing over $74 billion in sales will lose patent protection and therefore face the possibility of competition from generic manufacturers. Explore resources for what these issues mean for the industry

Stay Updated

Subscribe to receive updates from Deloitte's Life Sciences practice:
email icon   E-mail |   RSS icon   RSS ( What is RSS?) |  Twitter icon   Twitter